|
Heart failure is a varied clinical syndrome with a complex pathophysiology that is still being defined. This has made the optimal management of heart failure a difficult challenge for physicians. Almost six million Americans have heart failure, a progressive form of cardiovascular disease that inhibits the heart from pumping blood throughout the body and 550,000 new cases are diagnosed each year in the United States. About half of these patients die within five years after receiving a diagnosis of severe heart failure. Advanced heart failure remains one of the nation's most disabling and lethal medical conditions. It contributes to approximately 250,000 deaths each year, and the estimated economic burden of the syndrome exceeds $20 billion annually.
The study of adult stem cells and their role in treating cardiovascular disease is quickly becoming an acceptable mode of treatment. The challenge remains to identify the very best types of stem cells, refine delivery techniques, and establish the most effective doses of stem cells for specific cardiovascular problems. The faculty will address the role of continuous flow pumps in the treatment of patients with advanced heart failure, expanding the populations who benefit from current therapies, and enhancing conventional therapy for heart failure to achieve novel results. The faculty will review new targets for medical therapies and immunosuppressive therapies, application of alternative surgical techniques, next generation devices, gene expression therapies, and stem cell therapies. This symposium is designed to update physicians about the advanced treatment options available to patients with heart failure. This particular program is designed to address the various current and new treatment options and technologies for the growing heart failure population.
Learning Objectives
At the conclusion of this symposium, participants should be able to -
-
Summarize the natural history and pathophysiology of heart failure.
-
Identify patients who are at high risk of progression to end-stage heart failure.
-
Evaluate novel pharmacologic therapies for heart failure.
-
Describe current barriers to referral of patients for Mechanical Circulatory Support.
-
Assess how continuous flow physiology may affect patients who are transplanted and the potential for recovery.
-
Discuss the potential implications of gene expression therapy and stem cells in heart failure treatment.
-
Define the options regarding newer generation assist devices.
-
Summarize recent scientific advances related to the use of stem cells in treating heart failure, acute myocardial infarction and peripheral vascular disease.
-
Describe the mechanism of action of cell therapy in the treatment of cardiovascular disease.
- Discuss the use of stem cells in the regeneration of damaged heart tissues.
Target Audience
Adult Cardiologists, Cardiothoracic Surgeons, Heart Transplant Surgeons, Stem Cell Scientists and Researchers and Regenerative Medicine Specialists.
Preliminary Program Schedule
Thursday May 16, 2013
8:30 a.m. Registration and Coffee
9:45 a.m.
Welcome and Introductions
Stephen Westaby, BSc, MS, PhD
Session I
Prof. Michael Schneider and Prof. Paul Riley
10:00 - 10:30 a.m.
Heart Failure: Current Burden – Future Therapy
James T. Willerson, MD
10:30 – 11:00 a.m.
Limits on Transplantation – Role of Assist Devices
Jim Kirklin, MD
11:00 – 11:30 a.m.
Destination Therapy – Where Do We Stand?
Stephen Westaby, BSc, MS, PhD
11:30 - 12:15 p.m. Keynote Address
Stem Cells and the Heart: Future Directions
Prof. Sir Martin Evans (Nobel Prize Winner in Stem Cell Science)
12:15 p.m. Lunch and Exhibits
Session II
Is Myocardial Regeneration a Realistic Prospect?
James T. Willerson, MD & Prof. Sir Martin Evans
1:15 – 1:45 p.m.
Restoring Heart Function with Adult Stem Cells
Doris Taylor, PhD
1:45 – 2:15 p.m.
Treating Acute Myocardial Infarction with Adult Stem Cells
Andreas Zeiher, PhD
2:15 – 2:45 p.m.
Can We Activate Autologous Cardiac Stem Cells
TBD
2:45 – 3:15 p.m.
Manipulation of Stem Cells in the Repair of the Heart
Stephanie Dimmeler, PhD
3:15 – 3:45 p.m.
Bone Marrow Stem Cells and Acute Myocardial Infarction
Anthony Mathur, MD
3:45 p.m. Tea
Session III
Stem Cell Delivery
Andreas Zeiher, PhD and Jagat Narula, MD
4:00– 4:30 p.m.
Intra-Coronary Therapy for Myocardial Infarction
Timothy D. Henry, MD
4:30 – 5:00 p.m.
Direct Intra-Myocardial Injection
Emerson C. Perin, MD, PhD
5:00 – 5:30 p.m.
Clinical Status of Stem Cell Therapy in Myocardial Ischemia and Chronic Heart Failure
James T. Willerson, MD
5:30 – 6:00 p.m.
Use of c-kit Positive Stem Cells for the Treatment of Ischemic Heart Disease
Roberto Bolli, MD
6:00 - 6:30 p.m.
Conversion of Skin Cells to Cardiac Myocytes
Robert J. Schwartz, PhD
6:30 p.m. Adjourn
7:00 p.m. Reception
"How I Won the Nobel Prize"
Prof. Sir Martin Evans
Friday May, 17, 2013
8:00 a.m. Coffee
Session IV
Blood Pumps as the Basis for Myocardial Regeneration
Bartley Griffith, MD and Roberto Bolli, MD
8:30 - 8:55 a.m.
The Rotary Blood Pumps
Stephen Westaby, BSc, MS, PhD
8:55 - 9:20 a.m.
The Physiology of Left Ventricular Unloading and Function Improvement
Jagat Narula, MD
9:20 - 9:45 a.m.
Cardiac Imaging in Regeneration Therapy
Jagat Narula, MD
9:45 - 10:10 a.m.
Role of Adjuvant Therapy
Emma Birks, MD
10:10 - 10:35 a.m.
How the California Institute of Regenerative Medicine Functions and What Research Areas it is Funding
Mark Barr, MD 10:35 - 11:00 a.m.
Recovery from Heart Failure: Maximizing the Effect of the VAD by Repairing Valvular Defects
Robert Kormos, MD 11:00 - 11:25 a.m.
Bridge to Recovery in Clinic Practice
Roland Hetzer, MD 11:25 - 11:40 a.m. Coffee Session V
Pumps with Stem Cells
Emerson C. Perin, MD, PhD and Alain Carpentier, MD, PhD 11:40 a.m. - 12:05 p.m.
Do Destination Therapy Patients Do Better When Ventricular Function Improves?
Michael Acker, MD 12:05 - 12:30 p.m.
Can Myocardial Unloading Improve Cell Engraftment?
Mark Slaughter, MD 12:30 - 12:55 p.m.
The Bridge to Transplant Experimental Findings
Bartley Griffith, MD 12:55 - 1:20 p.m.
Preliminary Clinical Experience
Kyriakos Anastasiades, MD
1:20 p.m. Lunch with Guest Speaker
Adult Cardiac Progenitor Cells: Clonal Analysis, Molecular Signatures, Fate-mapping, and Bioprocessing
Prof. Michael Schneider Session VI
Cardiac Replacement - A Realistic Alternative?
Stephen Westaby, BSc, MS, PhD and Michael Acker, MD 2:30 - 3:00 p.m. Keynote Address
How it All Began
Denton A. Cooley, MD and Stephen Westaby, BSc, MS, PhD 3:00 - 3:30 p.m.
Total Artificial Hearts
Jack Copeland, MD 3:30 - 4:00 p.m.
Rotary Blood Pumps for Biventricular Support
Martin Strueber, MD 4:00 - 4:30 p.m.
Evolution and Current Status of Continuous Flow Pumps
O.H. Frazier, MD 4:30 p.m. Tea Session VII
Cardiac Regeneration Think Tank - The Way Forward
James Willerson, MD and Sir Martin Evans
5:00 - 6:00 p.m.
Discussion with Drs. James T. Willerson, Stephanie Dimmeler, Emerson Perin, Andreas Zeiher, Paul Riley, Tim Henry, Doris Taylor and Roberto Bolli 6:00 p.m. Adjourn
| 
